News | Vascular Closure Devices | September 16, 2022

Co-Author of the Karolinska 1000 Consecutive MANTA Vascular Closure Device Study to Present Learnings at the Transcatheter Cardiovascular Therapeutics (TCT) 2022 Conference

Results from Largest Ever Real-World Evaluation of the MANTA Device Demonstrated Safety and Effectiveness with Low Complication Rates and a Short Learning Curve 

Results from Largest Ever Real-World Evaluation of the MANTA Device Demonstrated Safety and Effectiveness with Low Complication Rates and a Short Learning Curve

September 16, 2022 — Teleflex Incorporated, a leading global provider of medical technologies, announced that Dr. Magnus Settergren, Asssociate Professor at the Karolinska Institutet, Interventional Cardiologist at Karolinska University Hospital, and Co-Author of the Percutaneous plug-based vascular closure device in 1000 consecutive transfemoral transcatheter aortic valve implantations Study, is scheduled to present at a Teleflex-sponsored Training Pavilion at the Transcatheter Cardiovascular Therapeutics (TCT) conference this Sunday, September 18, 2022 at 10:00 a.m. (ET). TCT is the Cardiovascular Research Foundation's (CRF) annual scientific symposium and the world's foremost educational forum specializing in interventional cardiovascular medicine. 

The Karolinska 1000 Consecutive MANTA Device Study—the largest ever real-world evaluation of the MANTA Device—demonstrated safety and effectiveness with low complication rates and a short learning curve.1 Results of this study were published in The International Journal of Cardiology

This single-center, observational study reviewed 1048 consecutive, unselected subjects undergoing transfemoral Transcatheter Aortic Valve Implantation (TAVI) from May 2017 to September 2020 at the Karolinska University Hospital in Stockholm, Sweden. The 18 French MANTA Device was used by five operators to close the femoral artery access site in 1000 subjects (48 excluded), with the primary outcome being the measure of vascular closure device (VCD)-related major complications according to Valve Academic Research Consortium (VARC)-2 definition criteria.1 

The study, which was not sponsored by Teleflex, demonstrated that MANTA Device related major vascular complications occurred in 4.2% of patients with no significant differences in preoperative characteristics between patients with and without MANTA Device related major vascular complication.1 This outcome is consistent with the results of the SAFE MANTA IDE Clinical Trial, published in 2019 in Circulation: Cardiovascular Interventions, which demonstrated a 4.2% VARC-2 Major Vascular Complication Rate, as well as The MARVEL Prospective Registry, published in 2020 in Catheterization & Cardiovascular Interventions, which demonstrated a 4.0% VARC-2 Major Vascular Complication Rate.2,3 

“As interventionalists, we frequently hear that one of the argued benefits of the MANTA Device compared to suture-based VCDs is a comparatively shorter learning curve; however, few studies have included a learning curve analysis,” said Dr. Settergren. “Our study found no significant differences in major complications between interventionalists, whether in their first 20 MANTA Device deployments, or even across the the first 100 procedures at the center.” 

“The findings of our study indicate that the MANTA Device is easy to learn and has a short learning curve, which is in line with our user experience. I look forward to presenting our learnings from this real-world experience to my colleagues at TCT this weekend,” concluded Dr. Settergren. 

About the MANTA Vascular Closure Device 

The MANTA Device is the first commercially available biomechanical vascular closure device designed specifically for large bore femoral arterial access site closure. The MANTA Device has now sold 100,000 units globally with 6+ years of commercial clinical experience. The device has been studied in 35+ clinical studies—25 focused on TAVI/TAVR.4 

For more information: https://www.teleflex.com/usa/en/ 

References: 

  1. Kastengren, M, Settergren, M, et al. Percutaneous plug-based vascular closure device in 1000 consecutive transfemoral transcatheter aortic valve implantations. International Journal of Cardiology. 2022; Vol 359. https://doi.org/10.1016/j.ijcard.2022.04.033 
  2. The SAFE MANTA IDE Clinical Trial. Study sponsored by Teleflex Incorporated or its affliates. 
  3. Kroon HG, Tonino PAL, Savontaus M, et al. Dedicated plug based closure for large bore access –The MARVEL prospective registry. Catheter Cardiovasc Interv. 2020;1–9. https://doi.org/10.1002/ccd.29439 
  4. Data on file at Teleflex. 

More TCT22 conference coverage 


Related Content

Videos | TCT

At TCT 2022, Jane Leopold, MD, a cardiologist at Brigham and Women’s Hospital; Director, Women's Interventional ...

Home November 03, 2022
Home
Videos | TCT

At TCT 2022, Jane Leopold, MD, a cardiologist at Brigham and Women’s Hospital; Director, Women's Interventional ...

Home October 26, 2022
Home
Feature | TCT | Christine Book

October 17, 2022 — Significant findings from the highly-anticipated EPIC-STEMI study were presented during a late ...

Home October 17, 2022
Home
Videos | TCT

At TCT 2022, Deepak Bhatt, MD, MPh, Executive Director of Interventional Cardiovascular Programs, Brigham and Women's ...

Home October 13, 2022
Home
Feature | TCT | By Christine Book

The 34th Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research ...

Home October 03, 2022
Home
News | TCT

September 22, 2022 — The recipient of the TCT 2022 Thomas J. Linnemeier “Spirit of Interventional Cardiology” Young ...

Home September 22, 2022
Home
News | TCT

September 19, 2022 — Puzzle Medical Devices, a provider of hemodynamic support in Heart Failure (HF), was selected as ...

Home September 20, 2022
Home
News | TCT

September 16, 2022 — Edwards Lifesciences Corporation, today announced the company's PASCAL Precision transcatheter ...

Home September 16, 2022
Home
News | TCT

September 16, 2022 — CathWorks announced today the schedule of key events for the company during Cardiovascular Research ...

Home September 16, 2022
Home
Subscribe Now